Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

individualized MVA-based vaccine TG4050

An off-the-shelf (OTS) individualized vaccine comprised of a modified Vaccinia virus Ankara (MVA) viral vector encoding tumor-specific neoantigens (TSNAs), with potential immunostimulatory and antineoplastic activities. Following administration of the individualized MVA-based vaccine TG4050, the neoantigens are expressed and presented to the immune system, which induces the activation of a specific cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing the patient-specific neoantigens.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	MVA-neoantigen vaccine TG4050 neoantigen-expressing MVA-based vaccine TG4050 TG4050 vaccine
Code name:	TG 4050 TG-4050 TG4050

individualized MVA-based vaccine TG4050

Search NCI's Drug Dictionary